ERBB2 and breast carcinoma: In subgroup analyses, we observed that, compared with women with HER2-positive breast cancer, women with HER2-negative breast cancer placed greater weight on PFS gains relative to the other attributes, although both groups placed the greatest weight on gains in PFS relative to other attributes.